Zobrazeno 1 - 10
of 456
pro vyhledávání: ''
Autor:
Leila Zemoura, Damien Treguer, Nicolas Girard, Marie Brevet, A. Chapelier, Didier Decaudin, Olivier Deas, Sophie Chateau-Joubert, Stefano Cairo, Rania El Botty, Sergio Roman-Roman, André Nicolas, Didier Meseure, Ivan Bièche, Sophie Vacher, Ludmilla de Plater, Elodie Montaudon, Elisabetta Marangoni, Catherine Daniel, Fariba Nemati, Adnan Naguez, Alain Livartowski
Publikováno v:
Oncotarget. 12:859-872
Significant rational is available for specific targeting of PI3K/AKT/mTOR pathway in the treatment of non-small cell lung cancer (NSCLC). However, almost all clinical trials that have evaluated Pi3K pathway-based monotherapies/combinations did not ob
miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells
Autor:
Carol S. Lutz, Nicholas J. Monteleone
Publikováno v:
Oncotarget
Lung cancer is a collection of aggressive tumors generally not diagnosed until late-stage, resulting in high mortality rates. The vast majority of non-small cell lung cancer (NSCLC) patients undergo combinatory chemotherapeutic treatment, which initi
Publikováno v:
Oncotarget. 11:4104-4114
Objective Women with inherited mutations in BRCA1 gene have a high (40-70%) genetic risk of developing ovarian cancer. Epidemiological studies suggest an inverse correlation between serum vitamin D (VD) levels and the risk of ovarian cancer, but ther
Autor:
Ulrich Keller, Andreas E. Albers, Raik Otto, Jan-Dirk Raguse, Jens Hoffmann, Theresa Eder, Konrad Klinghammer, Andreas M. Kaufmann, Ulrich Keilholz, Ingeborg Tinhofer, Oliver Politz
Publikováno v:
Oncotarget
Despite recent advances, the treatment of head and neck squamous cell carcinoma (HNSCC) remains an area of high unmet medical need. HNSCC is frequently associated with either amplification or mutational changes in the PI3K pathway, making PI3K an att
Publikováno v:
Oncotarget
The BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib. Resistance to BRAF inhibition in CRC arises in par
Autor:
Clementina Savastano, Maria Aliberti, G. Colantuoni, Liliana Montella, Olga Fiorentino, Sabino De Placido, Grazia Arpino, Salvatore Del Prete, Ferdinando Riccardi, Carlo Buonerba, Michele Orditura, A. Ruggiero, Giuseppe Buono, Antonio Febbraro, Pasquale Dolce
Publikováno v:
Oncotarget
Despite relevant medical advancements, metastatic breast cancer remains an uncurable disease. HER2 signaling conditions tumor behavior and treatment strategies of HER2 expressing breast cancer. Cancer treatment guidelines uniformly identify dual bloc
Autor:
Harumi Kagiwada, Yasuhiro Mitsui, Akihiro Hirao, Hiroshi Miyamoto, Tetsuji Takayama, Naoki Muguruma, Masashi Kitazawa, Tetsu Tomonari, Masahiro Sogabe, Hironori Tanaka, Tatsuya Taniguchi, Yasushi Sato, Katsuhisa Horimoto, Kazuhiko Fukui, Yasuteru Fujino, Takahiro Tanaka, Koichi Okamoto
Publikováno v:
Oncotarget
The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line LEN treatment, investigated the
Autor:
Timothy W. Corson, Bomina Park, Stephanie Merrigan, Breandán N. Kennedy, Zaheer Ali, Lasse Jensen
Publikováno v:
Oncotarget. 11:493-509
Aberrant ocular angiogenesis can underpin vision loss in leading causes of blindness, including neovascular age-related macular degeneration and proliferative diabetic retinopathy. Current pharmacological interventions require repeated invasive admin
Autor:
Ai Yamaguchi, Michiko Imamura, Yuki Okada, Tomoe Taji, Arisa Nishimukai, Tomoko Higuchi, Ayako Yanai, Takashi Morimoto, Takehiro Yanagawa, Ayako Bun, Hirofumi Suwa, Yuichiro Kikawa, Yasuo Miyoshi, Yoshimasa Miyagawa, Atsushi Sata, Hiromi Ozawa, Chiyomi Egawa, Kaori Takamoto, Yukie Fujimoto, Reiko Fukui, Junichi Inatome
Publikováno v:
Oncotarget
The effect of bevacizumab plus paclitaxel therapy on progression-free survival (PFS) is prominent; however, no overall survival (OS) benefit has been demonstrated. Our aim was to study the predictive efficacy of peripheral immune-related parameters,
Autor:
Gerasimos P. Sykiotis, Nadja Chevalier, Margot Calderoni, Adi Zheng, Gilles Dubuis, Panos G. Ziros, Christian Widmann, Olivier Dormond
Publikováno v:
Oncotarget
Oncotarget, vol. 10, no. 66, pp. 7058-7070
Oncotarget, vol. 10, no. 66, pp. 7058-7070
Sorafenib is the first-line drug used for patients with advanced hepatocellular carcinoma (HCC). However, acquired sorafenib resistance in cancer patients limits its efficacy. Here, we performed the first genome-wide CRISPR/Cas9-based screening on so